Press release year list 2021 2020 2019 2016
12/01/2021
Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant
11/29/2021
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
11/15/2021
Immunome Reports Third Quarter 2021 Financial Results
11/09/2021
Immunome to Present at the Stifel Healthcare Conference
10/20/2021
Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis
10/07/2021
Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
09/30/2021
Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
09/22/2021
Immunome to Present at the Cantor Global Healthcare Conference
09/15/2021
Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
09/07/2021
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing
08/19/2021
Immunome Reports Second Quarter 2021 Financial Results
07/20/2021
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
07/06/2021
Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference
06/30/2021
Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board
06/17/2021
Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors
05/27/2021
Immunome to Present at the Jefferies Virtual Healthcare Conference
05/20/2021
Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern
05/12/2021
Immunome Reports First Quarter 2021 Financial Results
04/26/2021
Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
04/26/2021
Immunome Announces $27 Million Private Placement
04/20/2021
Immunome Appoints Corleen Roche as Chief Financial Officer
03/30/2021
Immunome Appoints Dr. Dennis Giesing as Chief Development Officer
03/25/2021
Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
03/23/2021
Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies
02/18/2021
Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing
02/03/2021
Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment
02/01/2021
Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus